Abstract
We have studied the effect of food on the interaction of ofloxacin with sucralfate. Six healthy men took a single oral dose of ofloxacin (200 mg) on 4 occasions: alone after overnight fasting or after breakfast (non-fasting), and with sucralfate fasting or non-fasting.
There were no significant differences in the plasma concentration-time profiles of ofloxacin after ofloxacin alone between fasting and non-fasting conditions. On the other hand, the peak plasma concentration and AUC of ofloxacin after co-administration with sucralfate while fasting fell by 70 and 61 % compared with ofloxacin alone; the changes non-fasting were 39 and 31 % respectively. The interaction of ofloxacin with sucralfate was markedly reduced by food, but still could not be disregarded.
Similar content being viewed by others
References
Höffken G, Lode H, Wiley R, Glatzel TD, Sievers D, Olschewski T, Borner K, Koeppe T (1988) Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis 10 [Suppl 1]: S138-S139
Shiba K, Saito A, Miyahara T, Tachizawa H, Fujimoto T (1988) Effect of aluminum hydroxide, an antacid, on the pharmacokinetics of new quinolones in humans. Xenobiot Metab Disp 3: 717–722
Shishido H, Matsumoto K, Nugatake T, Tabuchi S (1988) Cross-over pharmacokinetics of NY-198 and ofloxacin in healthy volunteers and gastrectomized patients. Chemotherapy (Tokyo) 36 [Suppl 2]: 256–264
Flor S, Guay DRP, Opsahl JA, Tack K, Matzke GR (1990) Effect of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother 34: 2436–2438
Kawakami J, Sawada Y, Kihara E, Nakamura K, Yamada Y, Sakurai K, Seino T, Uchino K, Iga T (1992) Time-dependent inhibition of new quinolones absorption by antacids/anti-ulcer drugs containing metal cations and design for taking medicines. Jpn J Hosp Pharm 18: 1–21
Shiba K, Sakai O, Shimada J, Okezaki O, Aoki H, Hakusui H (1992) Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 36: 2270–2274
Brouwers JR, Kam HJ van der, Sijtsma J, Koks CH (1989) Important drug interaction of oral ciprofloxacin with sucralfate and magnesium citrate solution. Pharm Weekbl Sci 11 [Suppl E]: 13
Nix DE, Wilton JH, Schentag JJ, Parpia SH, Norman A, Goldstein HR (1989) Inhibition of norfloxacin absorption by antacids and sucralfate. Rev Infect Dis 11 [Suppl 5]: S1096
Katagiri Y, Naora K, Ichikawa N, Hayashibara M, Iwamoto K (1988) Simultaneous determination of ofloxacin, fenbufen and felbinac in rat plasma by high-performance liquid choromatography. J Chromatogr 431: 135–142
Gibaldi M, Perrier D (1975) Pharmacokinetics. Drugs and the pharmaceutical sciences, vol.1. Marcel Dekker New York
Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4: 879–885
Welling PG (1984) Interactions affecting drug absorption. Clin Pharmacokinet 9: 404–434
Ichihara N, Tachizawa H, Tsumura M, Une T, Sato K (1984) Phase I study on DL-8280. Chemotherapy (Tokyo) 32 [Suppl 1]: 118–149
Nakano M, Yamamoto M, Arita T (1978) Interactions of aluminum, magnesium, and calcium ions with nalidixic acid. Chem Pharm Bull 26: 1505–1510
Issopoulos PB (1989) Spectrophotometric determination of trace amounts of iron (III) with norfloxacin as complexing reagent. Analyst 114: 627–630
Kara M, Hasinoff BB, McKay DW, Campbell NRC (1991) Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 31: 257–261
Okabayashi Y, Hayashi F, Terui Y, Kitagawa T (1992) Studies on the interaction of pyridone carboxylic acids with metals. Chem Pharm Bull 40: 693–696
Parrish RH, Waller B, Gondalia, BG (1992) Sucralfate-warfarin interaction. Ann Pharmacother 26: 1015
Lebsack ME, Nix D, Ryerson B, Toothaker RD, Welage L, Norman AM, Schentag JJ, Sedman AJ (1992) Effect of gastric acidity on enoxacin absorption. Clin Pharmacol Ther 52: 252–256
Kobayashi H, Shimura M (1985) Phase I study with BAY o 9867 (ciprofloxacin). Chemotherapy (Tokyo) 33 [Suppl 7]: 140–170
Kawai M, Nakanishi M, Maekawa N (1984) Phase I study of AT-2266. Chemotherapy (Tokyo) 32 [Suppl 3]: 334–358
Nakashima M, Uematsu T, Takiguchi Y, Mizuno A, Kubo S, Takahara Y, Okezaki E, Nagata O (1988a) Phase I study on NY-198. Chemotherapy (Tokyo) 36 [Suppl 2]: 201–239
Abiko T, Ishihama A, Ogawa N, Uchida H, Murayama S, Hirai K, Oomori Y, Abe Y, Irikura T (1981) Phase I study on AM-715. Chemotherapy (Tokyo) 29 [Suppl 4]: 136–145
Nakashima M, Uematsu T, Kanemaru M (1988b) Phase I study of T-3262, a new pyridone-carboxylic acid derivative. Chemotherapy (Tokyo) 36 [Suppl 9]: 158–180
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawakami, J., Kotaki, H., Seino, T. et al. The effect of food on the interaction of ofloxacin with sucralfate in healthy volunteers. Eur J Clin Pharmacol 47, 67–69 (1994). https://doi.org/10.1007/BF00193481
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00193481